Brain Cancer
Dxcover Raises $11.9M to Bring Infrared Spectroscopy Cancer Detection Assay to Market
The firm is advancing what it describes as an infrared spectroscopy-based platform for early cancer detection, with initial data in brain tumors.
The company recently presented data on the use of its spectroscopic liquid biopsy test for the early-stage detection of multiple cancers at ASCO.
Brain Cancer Canada Funds Development of New Dx Sequencing Assay at St. Michael's Hospital
The group plans to develop and implement a custom gene sequencing assay intended to help rapidly diagnose brain cancers and inform molecularly targeted treatment.
NIH Launches New Childhood Cancer Genomics Program
Pediatric and young adult patients treated at facilities affiliated with the NCI-sponsored Children's Oncology Group gain new, broad access to tumor molecular profiling.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.